InsiderTrades.com logo
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.
Richard Daniell net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Richard Daniell Biography and Net Worth

VP of Teva Pharmaceutical Industries
Richard Daniell became Executive Vice President, European Commercial in November 2017, leading all activities of Teva Europe’s Generic, Specialty and over the counter (OTC) businesses as well as our Teva API and Medis B2B units.

With headquarters in The Netherlands, Teva Europe employs approximately 19,000 people in the region and covers 36 countries. Teva is Europe’s biggest provider of tried-and-trusted generic medicine, a leading provider of OTC medicines and a recognized innovator in CNS, respiratory medicines and biopharmaceuticals.

Before assuming this responsibility, Richard headed up Teva Europe Generics. Prior to that he served as Chief Operating Officer of International Markets and led the integration of the Actavis Generics business into Teva globally. Before that he served as General Manager for the United Kingdom and Ireland.

Richard received his B.Sc. degree in chemistry from the University of Auckland, New Zealand.

What is Richard Daniell's net worth?

The estimated net worth of Richard Daniell is at least $188,555.02 as of September 9th, 2020. Mr. Daniell owns 11,098 shares of Teva Pharmaceutical Industries stock worth more than $188,555 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Daniell may own. Additionally, Mr. Daniell receives an annual salary of $1,660,000.00 as VP at Teva Pharmaceutical Industries. Learn More about Richard Daniell's net worth.

How old is Richard Daniell?

Mr. Daniell is currently 57 years old. There are 6 older executives and no younger executives at Teva Pharmaceutical Industries. The oldest executive at Teva Pharmaceutical Industries is Mr. David R. Mcavoy J.D., Executive VP & Chief Legal Officer, who is 61 years old. Learn More on Richard Daniell's age.

What is Richard Daniell's salary?

As the VP of Teva Pharmaceutical Industries Limited, Mr. Daniell earns $1,660,000.00 per year. There are 3 executives that earn more than Mr. Daniell. The highest earning executive at Teva Pharmaceutical Industries is Mr. Richard D. Francis, President, CEO & Director, who commands a salary of $6,710,000.00 per year. Learn More on Richard Daniell's salary.

How do I contact Richard Daniell?

The corporate mailing address for Mr. Daniell and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Richard Daniell's contact information.

Has Richard Daniell been buying or selling shares of Teva Pharmaceutical Industries?

Richard Daniell has not been actively trading shares of Teva Pharmaceutical Industries within the last three months. Most recently, Richard Daniell sold 333 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $8.98, for a transaction totalling $2,990.34. Following the completion of the sale, the vice president now directly owns 11,098 shares of the company's stock, valued at $99,660.04. Learn More on Richard Daniell's trading history.

Who are Teva Pharmaceutical Industries' active insiders?

Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.

Are insiders buying or selling shares of Teva Pharmaceutical Industries?

During the last twelve months, insiders at the sold shares 10 times. They sold a total of 964,994 shares worth more than $14,909,765.00. The most recent insider tranaction occured on August, 1st when insider Eric A Hughes sold 24,537 shares worth more than $423,263.25. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.

Information on this page was last updated on 8/1/2024.

Richard Daniell Insider Trading History at Teva Pharmaceutical Industries

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2020Sell333$8.98$2,990.3411,098View SEC Filing Icon  
3/3/2020Sell991$11.77$11,664.0710,710View SEC Filing Icon  
9/18/2019Sell1,176$7.82$9,196.322,852View SEC Filing Icon  
9/9/2019Sell333$7.16$2,384.28696View SEC Filing Icon  
3/12/2019Sell715$15.69$11,218.35715View SEC Filing Icon  
3/4/2019Sell2,098$16.88$35,414.242,098View SEC Filing Icon  
9/18/2018Sell2,488$23.69$58,940.722,488View SEC Filing Icon  
9/10/2018Sell696$21.25$14,790.00696View SEC Filing Icon  
3/19/2018Sell1,297$17.89$23,203.331,297View SEC Filing Icon  
3/5/2018Sell1,108$19.28$21,362.24View SEC Filing Icon  
See Full Table

Richard Daniell Buying and Selling Activity at Teva Pharmaceutical Industries

This chart shows Richard Daniell's buying and selling at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $17.03
Low: $16.90
High: $17.17

50 Day Range

MA: $17.72
Low: $16.44
High: $18.78

2 Week Range

Now: $17.03
Low: $9.35
High: $19.31

Volume

3,400,364 shs

Average Volume

9,207,352 shs

Market Capitalization

$19.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.